
RESONANCE HEALTH LAUNCHES “RESONANCE CLINICAL”

Highlights

- New initiative to capitalise on the rapidly expanding global clinical trial marketplace
- To provide expanded services in Clinical Trial Management, Imaging and Central Laboratory CRO Services
- Leverages ‘decades-long-experience’ and global recognition in image analysis and related CRO services
- Consolidation of Murdoch University + UWA spaces into a dedicated Resonance Clinical ‘wet-lab’ facility
- Official launch at the national/international AusBiotech conference, Perth, 26-28 October 2022

Introducing “Resonance Clinical”

Resonance Health Ltd (ASX:RHT) (“Resonance Health” or “Company”) is pleased to advise the launch of its latest initiative, Resonance Clinical, which aims to capitalise on the lucrative and rapidly expanding global clinical trial marketplace, especially for new drugs and therapies being developed to treat liver diseases including iron-overload disorders and NAFLD/NASH, which is estimated to affect up to 30% of the global population¹. This initiative builds on Resonance Health’s decades-long experience providing high-quality image-analysis and clinical trial services to pharma/biotech and their clinical trial management partners, collectively referred to as clinical research organisations, or simply, CROs.

Resonance Clinical intends to provide full CRO services, as well as expanded imaging CRO and central laboratory CRO services to existing, as well as new pharmaceutical and biotech customers. Resonance Clinical, led by Program Director & Chief Scientist-Molecular Medicine, Dr Sherif Boulos, will draw on expertise from across the Resonance Health group. These existing capabilities include PhD scientists (with biomedical and physics training), clinical researchers, trained medical laboratory scientists, and a highly experienced QA/QC team.

As part of this initiative, equipment and personnel will be relocated from Murdoch University and UWA into a larger, purpose designed, dedicated Resonance Clinical laboratory at Bentley Tech Park in Perth, Western Australia. This arrangement will deliver immediate cost-savings, provide greater autonomy, versatility and enhanced long-term security and importantly, allow Resonance Clinical to offer large numbers of high-value clinical assessments for drug trials. Presently, the Company’s commercially available MRI phantom products, used to calibrate MRI machines, are manufactured at UWA and the molecular R&D program utilises labs at Murdoch University.

The Company is in discussions with a variety of potential collaborators and customers regarding Resonance Clinical’s enhanced service offering. Resonance Clinical will be formally launched at the national/international AusBiotech conference on 26-28 October 2022, during which The Hon. Minister Stephen Dawson MLC, whose portfolio includes innovation and medical research, is scheduled to visit the Resonance Clinical booth. To learn more about Resonance Clinical, please visit www.resonanceclinical.com.

Resonance Clinical Program Director & Chief Scientist (Molecular Medicine), Dr. Sherif Boulos, commented:

“This initiative will unleash the full potential of the Company’s scientific, commercial and compliance capabilities that have evolved and strengthened over the years. By expanding its services in this way, Resonance Health will open itself up to new lucrative markets that demand high-value, high-quality services that we are familiar with and qualified to provide, but in the past have only provided in a limited way.”

Managing Director of Resonance Health, Mr. Mitchell Wells, commented:

“Resonance Health is known globally for its services and technologies relating to the liver and has assisted many pharma customers with their development of drugs to treat liver diseases, which is also our highest profit margin work. We currently provide services to 10 clinical trials and by leveraging the full range of capabilities across the group, including in liver ‘wet-lab’ molecular medicine, we can provide many more services to clinical trials. Some customers are asking more of us than has historically been the case and we have a great opportunity to capitalise on this, from within our existing customer base, and from the mostly untapped, prolific global liver clinical trial marketplace. The Resonance Clinical initiative is specifically aimed at new commercialisation opportunities from enhanced CRO service provision and new central ‘wet’ lab services.”



Powered by Resonance Health

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Ltd.

For further information please contact:

Mitchell Wells – Managing Director

E: mitchellw@resonancehealth.com

P: +61 (0)8 9286 5300

Nick Allan – CFO & Company Secretary

E: nicholasa@resonancehealth.com

P: +61 (0)8 9286 5300

About Resonance Health

Resonance Health is an Australian health services and technology and services company. The Company’s services are used globally by clinicians in the management of diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high quality quantitative assessments essential in managing diseases and drug development.

Resonance Health’s dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-assisted, non-invasive MRI-based device for the automated real-time assessment of LIC in patients, calibrated against the global gold standard, FerriScan®.

- **HepaFat-Scan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFat-AI®**, an AI-assisted, non-invasive device for the automated real-time multi-metric assessment of liver-fat in patients, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-assisted, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*. CardiacT2* is TGA and CE Marking regulatory cleared.

The Company has a development pipeline of additional medical imaging analysis products and services, including **CardiacT2*-AI** an AI tool for the automated analysis and quantification of cardiac-iron levels and **LungSmart (Alert-PE™)**, an AI tool for the automated review of chest CT scans of patients with suspected PE.

Stakeholders, including clinicians, patients, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on Facebook, LinkedIn, and Twitter.

FOLLOW US



/Resonance-Health-Ltd



/ResonanceHealth



/ResonanceHealthLtd

¹ *Nonalcoholic fatty liver disease and cardiovascular diseases phenotypes, Glandomenico Bisaccia et al, SAGE Open Medicine Volume 8: 1-15, 21 May 2020.*